Peptide from the end of an IGF-1 variant that muscle produces after exertion. Results in cells are contradictory and there are no human studies.
Regulatory status
Not approved
Family
Peptide derived from an IGF-1 isoform (E domain)
Scientific evidence
Low
Number of findings
2
Where it acts
Bones and muscles
Also known as
MGF, mechano growth factor, IGF-1Ec, PEG-MGF
Regulatory status
FDA (US): Not approved. The FDA notes that there are no human exposure data.
EMA (EU): Not approved
Dose
There is no established dose in humans.
Safety
No human safety data or purity guarantees. Its use only makes sense in research or under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
Activation of human muscle cells in culture
improvesLowin vitro (A)animals / laboratory
In cultured human muscle cells, the peptide extended their proliferative lifespan and increased their fusion in young cells, but not in cells from older people.
It was proposed to activate muscle stem cells (satellite cells) after muscle damage, before mature IGF-1 acts. Independent studies have not been able to reproduce that effect.
What the evidence says
In people
There are no published trials in people.
In animals or the laboratory
Activation of human muscle cells in culture. In cultured human muscle cells, the peptide extended their proliferative lifespan and increased their fusion in young cells, but not in cells from older people. PubMed 21354439
No effect in a replication study. An independent study found no effect on the proliferation or differentiation of myoblasts or muscle stem cells, at doses up to 500 ng/mL. PubMed 24253050